Title  | Date  | Price  |
|---|
Savient Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Athersys, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Millipore Corporation - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Rigel Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Nissan Chemical Industries, Ltd. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due to Increasing Genericization
| Jun 2009 |
£9,270 |
Gedeon Richter Plc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Express Scripts, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Ipsen S.A. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Mission Pharmacal Company - Strategic Analysis Review
| Jun 2009 |
£77 |
Vital Signs, Inc. - Strategic Analysis Review
| Jun 2009 |
£77 |
Arrow International, Inc. - Strategic Analysis Review
| Jun 2009 |
£77 |
Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Apotex, Inc. - Strategic Analysis Review
| Jun 2009 |
£77 |
E. I. du Pont de Nemours and Company - Strategic Analysis Review
| Jun 2009 |
£77 |
Les Laboratoires Servier - Strategic Analysis Review
| Jun 2009 |
£77 |
Highmark Inc. - Strategic Analysis Review
| Jun 2009 |
£77 |
CHRISTUS Health - Strategic Analysis Review
| Jun 2009 |
£77 |
Israel Pharmaceuticals and Healthcare Report Q3 2009
| Jun 2009 |
£250 |
Nanotechnology: Players, products & prospects to 2018 (Volume II)
| Jun 2009 |
£595 |
WellPoint, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Tenet Healthcare Corporation - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Nabi Biopharmaceuticals - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Kuwait Pharmaceuticals and Healthcare Report Q3 2009
| Jun 2009 |
£250 |
Health Management Associates, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
AmerisourceBergen Corporation - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
ALK-Abello A/S - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Acorda Therapeutics, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Waters Corporation - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
LCA-Vision Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Asian Medical Tourism Analysis (2008-2012)
| Jun 2009 |
£840 |
Isis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
World Sleep Disorders Market Analysis 2009-2024
| Jun 2009 |
£1,499 |
Global In Vitro Diagnostic Market Analysis
| Jun 2009 |
£960 |
World Respiratory Disorders Market 2009-2024
| Jun 2009 |
£1,499 |
Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Genentech, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Idenix Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Watson Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Jun 2009 |
£77 |
Private healthcare market in Poland 2009 Development forecast for 2009-2011 Plus: Non-public hospitals in Poland database
| May 2009 |
£1,555 |
Global Coronary Stent Market Report
| May 2009 |
£515 |
Canadian Healthcare IT 2009-2013 Forecast
| May 2009 |
£2,705 |
Psychologists, Social Workers & Marriage Counseling in the US IBISWorld Industry Report
| May 2009 |
£390 |
Canadian Healthcare IT 20092013 Forecast
| May 2009 |
£2,705 |
U.S. Bone and Joint Health Ingredients Market
| May 2009 |
£3,910 |
Good Clinical Practice A Question & Answer Reference Guide 2009
| May 2009 |
£28 |
Healthcare Industry in Russia - IT Market Assessment
| May 2009 |
£600 |
Health and Wellness - Nutritionals in South Korea
| May 2009 |
£800 |
Healthcare Industry in South Africa - IT Market Assessment
| May 2009 |
£600 |
Worldwide Heart Valve Market Report: 2009 Edition
| May 2009 |
£485 |
Understanding Obama's Healthcare Reforms President Obama's Plans for the U.S.
| May 2009 |
£59 |
Healthcare ICT and Compliance
| May 2009 |
£1,200 |
Mylan Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
NeoPharm, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Lonza Group Ltd - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Meiji Seika Kaisha, Ltd. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Maxygen, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Noven Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Omnicare, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Novavax, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Myriad Genetics, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
MDRNA, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Neose Technologies, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Kindred Healthcare, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Human Genome Sciences, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Humana Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
GTC Biotherapeutics, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
GTx, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
ImmunoGen, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
IMS Health Incorporated - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
OSI Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
InterMune, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Japan Tobacco Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
King Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Publix Super Markets, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
UnitedHealth Group Incorporated - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Vertex Pharmaceuticals Incorporated - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Virbac Corporation - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
ViroPharma Incorporated - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
UCB Group - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
A Practical Guide to Licensing Herbal Medicinal Products First Edition
| Apr 2009 |
£250 |
Abortion Clinics, Fertility & Family Planning Centers in the US IBISWorld Industry Report
| Apr 2009 |
£390 |
Early Stage Drug Safety Strategies and Risk Management Maximizing Opportunities towards Achieving Clinical Success
| Apr 2009 |
£2,305 |
Robotic Surgery Market Report: 2009 Edition
| Apr 2009 |
£485 |
Healthcare Communication First Edition
| Apr 2009 |
£30 |
Takara Holdings Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Santarus, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
PDL BioPharma, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Pfizer Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Pain Therapeutics, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Par Pharmaceutical Companies, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Res-Care, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
SYSCO Corporation - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Sciele Pharma, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
Sunesis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
SuperGen, Inc. - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |
OPG Groep - Financial and Strategic Analysis Review
| Apr 2009 |
£77 |